Cancer Causes & Control

, Volume 15, Issue 3, pp 255–265 | Cite as

Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer

  • Elizabeth A. PlatzEmail author
  • Michael F. Leitzmann
  • Bruce W. Hollis
  • Walter C. Willett
  • Edward Giovannucci


Objective: The hormone 1,25-dihydroxyvitamin D (1,25(OH)2D) promotes prostate epithelial cell differentiation in vitro and thus, several groups have hypothesized that men who systemically have lower levels of 1,25(OH)2D may be at increased risk for prostate cancer. To address this hypothesis, we evaluated the association of circulating concentrations of 1,25(OH)2D and its precursor 25-hydroxyvitamin D (25(OH)D) with subsequent risk of prostate cancer.

Methods: Prostate cancer cases were 460 men in the Health Professionals Follow-up Study who were diagnosed through 1998 after providing a blood specimen in 1993/95. 90.2% of the cases were organ confined or had minimal extraprostatic extension. An equal number of controls who had had a screening PSA test after blood draw were individually matched to cases on age, history of a PSA test before blood draw, and time of day, season, and year of blood draw. Plasma 1,25(OH)2D and 25(OH)D concentrations were determined by radio-immunosorbant assay blindly to case–control status. Odds ratios (OR) of prostate cancer and 95% confidence intervals (CI) were estimated from conditional logistic regression models mutually adjusting for quartiles of 1,25(OH)2D and 25(OH)D concentrations and for suspected prostate cancer risk factors. Quartile cutpoints were determined separately by season of blood draw using the distributions among controls.

Results: Mean concentrations of 1,25(OH)2D and 25(OH)D were slightly, but not statistically significantly (p= 0.06 and 0.20, respectively), higher in cases (34.3 ± 7.1 pg/ml and 24.6 ± 7.7 ng/ml, respectively) than in controls (33.5 ± 7.1 pg/ml and 23.9 ± 8.2 ng/ml, respectively). The OR of prostate cancer comparing men in the top to bottom quartile of 1,25(OH)2D was 1.25 (95% CI: 0.82–1.90, p-trend = 0.16). For 25(OH)D the OR of prostate cancer comparing the top and bottom quartiles was 1.19 (95% CI: 0.79–1.79, p-trend = 0.59). These findings did not vary by level of the other metabolite, age at diagnosis, family history of prostate cancer, or factors that are thought to influence 25(OH)D levels.

Conclusion: In this prospective study, we did not observe an inverse association between plasma concentrations of 1,25(OH)2D or 25(OH)D and incident prostate cancer, although we cannot rule out potential effects at later stages of the disease.

cohort study prostate cancer risk vitamin D 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307–1311.PubMedGoogle Scholar
  2. 2.
    Corder EH, Guess HA, Hulka BS, et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467–472.PubMedGoogle Scholar
  3. 3.
    Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6: 235–239.PubMedGoogle Scholar
  4. 4.
    Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 121–126.PubMedGoogle Scholar
  5. 5.
    Nomura AM, Stemmermann GN, Lee J, et al. (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer. Cancer Causes Control 9: 425–432.PubMedGoogle Scholar
  6. 6.
    Ahonen MH, Tenkanen LT, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847–852.PubMedGoogle Scholar
  7. 7.
    Hollis BW, Kamerud JQ, Salvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labelled tracer. Clin Chem 39: 529–533.PubMedGoogle Scholar
  8. 8.
    Fraser DR (1980) Regulation of the metabolism of vitamin D. Physiol Rev 60: 551–613.PubMedGoogle Scholar
  9. 9.
    Bahnson RR, Oeler T, Trump D, Smith D, Schwartz GG (1993) Inhibition of human prostatic carcinoma cell lines by 1,25 dihydroxyvitamin D3 and vitamin D analogs. J Urol 149: 471a.Google Scholar
  10. 10.
    Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D (1994) Antiproliferative effects of 1,25-dihydroxyvita-min D3 on primary cultures of human prostatic cells. Cancer Res 54: 805–810.PubMedGoogle Scholar
  11. 11.
    Drivdahl RH, Loop SM, Andress DL, Ostenson RC (1995) IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 26: 72–79.PubMedGoogle Scholar
  12. 12.
    Esquenet M, Swinnen JV, Heyns W, Verhoeven G (1996) Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1a,25-dihydroxycholecalciferol, all-transretinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28: 182–194.PubMedGoogle Scholar
  13. 13.
    Hsieh T-C, Ng C-Y, Mallouh C, Tazaki H, Wu JM (1996) Regulation of growth, PSA/PAP and androgen receptor expression by 1a,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Comm 223: 141–146.PubMedGoogle Scholar
  14. 14.
    Giovannucci E, Rimm EB, Wolk A, et al. (1958) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58: 442–447.Google Scholar
  15. 15.
    Stampfer MJ, Willett WC, Speizer FE, et al. (1984) Test of the National Death Index. Am J Epidemiol 119: 837–839.PubMedGoogle Scholar
  16. 16.
    Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL (1996) Quanti.cation of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem 42: 586–592.PubMedGoogle Scholar
  17. 17.
    Thomas CL, ed. (1989) Taber's Cyclopedic Medical Dictionary. 16th edn. Philadelphia: F.A. Davis Company.Google Scholar
  18. 18.
    Gloth FM, Tobin JD, Sherman SS, Hollis BW (1991) Is the recommended daily allowance for vitamin D too low for the homebound elderly. J Am Geriatr Soc 39: 137–141.PubMedGoogle Scholar
  19. 19.
    Reichel H, Koeffler HP, Norman AW (1989) The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980–991.PubMedGoogle Scholar
  20. 20.
    Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952–1960.PubMedGoogle Scholar
  21. 21.
    Miller GJ, Stapleton GE, Hedlund TE, Moffatt KA (1995) Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1a,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1: 997–1003.PubMedGoogle Scholar
  22. 22.
    Hedlund TE, Moffatt KA, Miller GJ (1996) Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1a,25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137: 1554–1561.PubMedGoogle Scholar
  23. 23.
    Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR (1995) 1,25-dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 46: 365–369.PubMedGoogle Scholar
  24. 24.
    Lucia MS, Anzano MA, Slayter MV, et al. (1995) Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 55: 5621–5627.PubMedGoogle Scholar
  25. 25.
    Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami H-O, Wolk A (1998) Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9: 559–566.PubMedGoogle Scholar
  26. 26.
    Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J (2000) Diet and prostate cancer risk in a cohort of smokers, with a specificfocus on calcium and phosphorus (Finland). Cancer Causes Control 11: 859–867.PubMedGoogle Scholar
  27. 27.
    Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 form 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7: 391–395.PubMedGoogle Scholar
  28. 28.
    Sung V, Feldman D (2000) 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164: 133–143.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Elizabeth A. Platz
    • 1
    Email author
  • Michael F. Leitzmann
    • 2
  • Bruce W. Hollis
    • 3
  • Walter C. Willett
    • 4
  • Edward Giovannucci
    • 4
  1. 1.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Division of Cancer Etiology and PreventionNational Cancer InstituteRockvilleUSA
  3. 3.Department of PediatricsMedical University of South CarolinaCharlestonUSA
  4. 4.Departments of Epidemiology and NutritionHarvard School of Public Health, Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham & Women's HospitalBostonUSA

Personalised recommendations